Search Medical Condition
Please enter condition
Please choose location from dropdown

Shirley, New York Clinical Trials

A listing of Shirley, New York clinical trials actively recruiting patient volunteers.

RESULTS

Found (19) clinical trials

A Study to Evaluate the Efficacy and Safety of RO6867461 in Participants With Diabetic Macular Edema (YOSEMITE)

This study will evaluate the efficacy, safety, and pharmacokinetics of RO6867461 administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).

Phase

0.0 miles

Learn More »

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO

A Randomized, Masked, Controlled Trial to Study the Safety and Efficacy of Suprachoroidal CLS-TA With Intravitreal Anti-VEGF Agent in Subjects With Retinal Vein Occlusion

Phase

0.14 miles

Learn More »

Bronchoprovocation Study to Evaluate the Pharmacodynamics of Albuterol Sulfate Inhalation Aerosol eq 90 mcg Base

This randomized, single-dose, double-blind, double-dummy, four-period, four-sequence, four-treatment, placebo and active controlled, comparative, multiple-center, crossover-design bronchoprovocation study has been designed to evaluate the pharmacodynamic equivalence of albuterol sulfate HFA inhalation aerosol, eq 90 mcg base (Amneal Ireland Limited) to PROAIR HFA (albuterol sulfate) Inhalation Aerosol, eq 90 mcg base (Teva ...

Phase

1.75 miles

Learn More »

A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2

This study will assess the gastrointestinal (GI) tolerability of ALKS 8700 in adult subjects with RRMS

Phase

6.85 miles

Learn More »

Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)

To evaluate the effects of BIIB033 versus placebo on disability improvement over 72 weeks and to evaluate the effects of BIIB033 versus placebo on additional measures of disability improvement.

Phase

6.85 miles

Learn More »

A Phase 3 Randomized Multi-center Double-blinded Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)

This is a phase 3, randomized, multi-center, double-blinded, active-controlled study that is primarily designed to assess the Annualized Relapse Rate (ARR) and safety/tolerability of ublituximab/oral placebo (TG-1101; UTX) as compared to teriflunomide/ IV placebo in subjects with relapsing MS.

Phase

6.85 miles

Learn More »

Palbociclib in Real World Practice

This Non-Interventional Study will describe and analyze the clinical use of palbociclib in routine clinical practice in the treatment of advanced breast cancer.

Phase N/A

6.85 miles

Learn More »

ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer

This is an international, multi-center, open-label, randomized, Phase III study in patients with metastatic TNBC refractory or relapsing after at least 2 prior chemotherapies (including a taxane) for their metastatic disease. The primary objective of this study is to compare the efficacy of sacituzumab govitecan to the treatment of physician's ...

Phase

6.85 miles

Learn More »

Observational Registry of H.P. Acthar Gel for Multiple Sclerosis Relapse

H.P. Acthar Gel (repository corticotropin injection) contains a porcine analogue of adrenocorticotropic hormone (ACTH) for intramuscular or subcutaneous use. H.P. Acthar Gel (Acthar Gel) was initially approved by the FDA in 1952 and has multiple indications of use. This registry will evaluate the use of Acthar Gel for the treatment ...

Phase N/A

6.85 miles

Learn More »

Dimethyl Fumarate (DMF) Observational Study

Patients aged 12 to under 18 may be included where enrollment of pediatric patients in this study is considered observational and is permissible by local regulations.

Phase N/A

6.85 miles

Learn More »